Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F-18 Florastamin - FutureChem/HTA Co/IASON/Moltek

Next Previous
X
Search
Drug Profile

F-18 Florastamin - FutureChem/HTA Co/IASON/Moltek

Alternative Names: 18F labeled FC303 injection; 18F-FC303; [18F]FLOR (FC303) injection; [18F]FLOR (FC303) PET/CT imager; [18F]Florastamin; Florastamin 18F

Latest Information Update: 29 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FutureChem
  • Developer FutureChem; HTA CO; IASON
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 29 Sep 2024 Phase I development in Prostate-cancer (Diagnosis) is still ongoing (Futurechem pipeline, September 2024)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA (IV, Injection)
  • 21 Aug 2023 Phase-III clinical trials in Prostate cancer (Diagnosis) in China (IV) (NCT06011304)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top